ClinicalTrials.gg
Not yet recruitingNCT07354828Updated Jan 21, 2026

Optimization and Validation of Quality Control Indicators for Coronary Revascularization Based on Antiplatelet Therapy

An observational study in Acute Coronary Syndrome (ACS), High Bleeding Risk (HBR) and Coronary Artery Disease (CAD), sponsored by Shenyang Northern Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Shenyang Northern Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital — 5 open to participants now, 5 under way, none of them phase 3. Acute Coronary Syndrome · Shenyang Northern Hospital.

Started
2025
the only one that year
Observational
2 of 12
1 open now
Registered
9th of 12
by date

Among the 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital, this one is the only one that started in 2025, is one of 2 observational ones, and was the 9th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

5 of the 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital, or all of them as a file.
02

Study summary

Study Purpose Coronary heart disease (CAD) is a leading global cause of death, with Acute Coronary Syndrome (ACS) as its acute and life-threatening subtype. Percutaneous Coronary Intervention (PCI) plus stent implantation is the first-line treatment for ACS, and post-PCI Dual Antiplatelet Therapy (DAPT, aspirin + P2Y₁₂ inhibitor) is core for thrombosis prevention but increases bleeding risk. Approximately 40% of ACS patients are classified as High Bleeding Risk (HBR). China lacks a unified DAPT quality control system, and the predictive value of the OPT-CAD ischemic risk score for this population remains unvalidated. This study aims to: 1) Evaluate the feasibility and influencing factors of the DAPT quality control system in HBR ACS patients post-PCI; 2) Verify the accuracy of the OPT-CAD score in predicting ischemic risk, providing evidence for personalized treatment.

Eligibility Criteria Inclusion Criteria Aged ≥18 years; Diagnosed with ACS and implanted with at least one drug-eluting stent (DES) during PCI; Meets ARC-HBR (Academic Research Consortium for High Bleeding Risk) HBR definition (1 major criterion or 2 minor criteria); Able to complete OPT-CAD scoring; Tolerates 12-month DAPT (physician assessment); Signs informed consent. Exclusion Criteria Allergy to aspirin, clopidogrel, ticagrelor, or other study-related antiplatelet drugs; Severe ischemia or major bleeding during current hospitalization; Terminal illness with life expectancy \<1 year; Pregnant or planning pregnancy within 1 year; Enrolled in other ongoing clinical studies. Study Process

This is a multi-center prospective cohort study (we will follow eligible patients over 12 months to collect real-world data without changing their standard care) recruiting 3,500 participants nationwide. Post-enrollment:

Receive 6-12 months of standard DAPT (regimen determined by your physician); Follow-ups at 1 month (±7 days), 3 months (±14 days), 6 months (±30 days), and 12 months (±30 days) post-PCI (via phone or outpatient visit) to collect medication adherence, bleeding/ischemic events, and clinical outcomes; Confidential data collection via a secure Electronic Data Capture (EDC) system. Study Endpoints Primary Endpoints Feasibility of the DAPT quality control system, inter-hospital differences in DAPT use, 6-12 month DAPT completion rate, and impact of DAPT interruption on patient outcomes; Accuracy of the OPT-CAD score in predicting ischemic risk for HBR patients. Secondary Endpoints 12-month bleeding event rates (BARC 1-5 types, including minor bleeding like puncture site bleeding and major bleeding like intracranial hemorrhage); 12-month ischemic event rates (including target lesion failure-cardiac death, target vessel-related myocardial infarction, or target lesion revascularization-all-cause death, ischemic stroke, definite stent thrombosis, etc.); DAPT interruption rate, P2Y₁₂ inhibitor discontinuation rate (≥1 week), and aspirin discontinuation rate (≥1 week).

Key Information for Participants Voluntary participation: You may withdraw anytime without penalty or loss of medical benefits; Confidential data protection: Personal information will be anonymized with a unique study ID; Free study-related assessments and follow-ups; Prompt medical care will be provided for any adverse events. For inquiries, contact the study team at the participating hospital.

Read the detailed description

This study is a prospective, multicenter, observational registry cohort study designed to evaluate real-world dual antiplatelet therapy (DAPT) management in high-bleeding-risk patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).

Eligible patients undergoing PCI will be screened against the study inclusion and exclusion criteria. Patients who meet eligibility requirements will be invited to participate, provide informed consent, and be assigned a unique study identification number. Study participation will not alter routine clinical care, and all treatment decisions, including DAPT regimen selection and duration, will be determined by the treating physician in accordance with standard clinical practice.

A total of approximately 3,500 evaluable patients are planned to be enrolled across multiple centers nationwide, including prefecture-level/district/county hospitals and provincial or national key hospitals. Enrollment will reflect real-world clinical practice, with no more than a predefined proportion of patients enrolled at any single site.

Clinical data will be collected prospectively at baseline and during routine follow-up at approximately 1, 3, 6, and 12 months following PCI. Collected information will include patient characteristics, PCI-related data, DAPT treatment patterns, and clinical outcomes.

The registry is designed to characterize real-world application of a DAPT quality control indicator system and to evaluate the prognostic performance of the OPT-CAD score in high-bleeding-risk ACS patients. Findings from this study are expected to provide real-world evidence to support standardized DAPT quality control and personalized antiplatelet therapy in this high-risk population.

03

Conditions studied

  • Acute Coronary Syndrome (ACS)
  • High Bleeding Risk (HBR)
  • Coronary Artery Disease (CAD)

Keywords

  • Dual Antiplatelet Therapy (DAPT)
  • Acute Coronary Syndrome (ACS)
  • High Bleeding Risk (HBR)
  • Percutaneous Coronary Intervention (PCI)
  • OPT-CAD Score
  • Quality Control Indicators
  • Coronary Revascularization
  • Prospective Cohort Study
  • Real-World Research
  • Bleeding Events
  • Ischemic Events
  • Medication Adherence
  • Post-PCI Prognosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study participants will be selected from inpatients admitted to multiple nationwide medical centers (including prefecture/county-level hospitals and provincial/national key hospitals) who are clinically diagnosed with Acute Coronary Syndrome (ACS) and undergo Percutaneous Coronary Intervention (PCI) with Drug-Eluting Stent (DES) implantation during hospitalization. The source population consists of ACS patients who meet the clinical diagnostic criteria, require PCI treatment, and are potentially at high bleeding risk (may fulfill ARC-HBR criteria). Patients with clear contraindications to Dual Antiplatelet Therapy (DAPT), inability to complete follow-up, or other conditions that make them unsuitable for the study are excluded from the source population.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years
  • Clinically diagnosed with ACS and received implantation of at least one drug-eluting stent (DES)
  • Meets 1 major criterion or 2 minor criteria of the ARC-HBR high-bleeding-risk definition
  • Able to complete the OPT-CAD score calculation
  • Judged by the investigator to tolerate DAPT for at least 12 months
  • Signed the form

Exclusion criteria

Exclusion Criteria:

  • Allergy to study medications such as aspirin, clopidogrel, or ticagrelor
  • Occurrence of major ischemic or bleeding events during the current hospitalization
  • Presence of other severe diseases with a of less than one year
  • Pregnancy, or women of who plan to become pregnant within one year
  • Current participation in another clinical study and still within its observation period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,500 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Low Ischemic Risk (OPT-CAD < 90)

    This group includes patients with high bleeding risk (meeting ARC-HBR criteria) who are diagnosed with Acute Coronary Syndrome (ACS) and have undergone Percutaneous Coronary Intervention (PCI) with at least one Drug-Eluting Stent (DES) implantation. All participants have an OPT-CAD score \< 90, indicating low ischemic risk. They receive routine Dual Antiplatelet Therapy (DAPT) for 6-12 months as per clinical guidelines (specific regimens determined by attending physicians). During the 12-month follow-up, data on DAPT adherence, discontinuation reasons, and clinical outcomes (bleeding/ischemic events, mortality) will be collected to compare with the moderate/high ischemic risk group.

  • Moderate/High Ischemic Risk (OPT-CAD ≥ 90)

    This group comprises patients who meet the same baseline criteria as Group 1: high bleeding risk (ARC-HBR positive), ACS diagnosis, PCI with DES implantation, and ability to tolerate 12-month DAPT. The key distinction is an OPT-CAD score ≥ 90, classifying them as moderate/high ischemic risk. They also receive standard 6-12 month DAPT (regimens decided by clinicians). Follow-up procedures and data collection are identical to Group 1, aiming to verify the predictive value of the OPT-CAD score by comparing clinical outcomes between the two groups.

06

What researchers measure

Primary outcomes

  1. The overall composite of 11 performance measures for DAPT-based Quality Control Standard System for Coronary Artery Disease Revascularization.

    The proportion of ACS patients scheduled for stent implantation during PCI who undergo risk stratification; The proportion of ACS patients undergoing PCI who initiate DAPT during the procedure; The proportion of ACS patients who maintain DAPT for at least 12 months after PCI; In patients at "high bleeding risk", the proportion of patients whose DAPT regimens are adjusted according to risk; The proportion of patients with implanted BRS who maintain DAPT for more than 12 months; The proportion of patients receiving alternative DAPT regimens due to drug intolerance or allergy; The proportion of implementation of optimized regimens combining anticoagulation with DAPT; The proportion of DAPT adjustment following bleeding events; Incidence of ischemic events: cardiac death, ischemic stroke, definite stent thrombosis, TVR, and TLF; Incidence of bleeding events: BARC Types 3/5 bleeding; The proportion of patients adherent to standardized DAPT.

    Time frame: 12 months

  2. Accuracy of the OPT-CAD score in predicting ischemia risk in high-bleeding-risk patients.

    The OPT-CAD score (Optimal antiPlatelet Therapy for Chinese patients with Coronary Artery Disease) is an ischemic risk scoring system developed based on the Chinese OPT-CAD registry study (107 centers, 14,032 patients). It is specifically used to predict long-term ischemic events and all-cause mortality in Chinese patients with coronary artery disease, especially those with acute coronary syndrome (ACS). OPT-CAD score ranges from 0 to 257 points in total. Patients are divided into three risk levels based on their total scores, corresponding to different incidences of ischemic events:Low risk 0-90 points ;Medium risk 91-150 points High risk ≥151 points.

    Time frame: 12 months

Secondary outcomes

  1. Incidence of first BARC 3/5 bleeding within 12 months;

    Incidence rate of major bleeding events (Bleeding Academic Research Consortium (BARC)\[1\] defined Type 3 and Type 5 bleeding) \[1\]Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. PMID: 21670242.

    Time frame: 12 months

  2. Incidence of first BARC 2/3/5 bleeding within 12 months

    Incidence rate of bleeding events (Bleeding Academic Research Consortium (BARC)\[1\] defined Type2, Type 3 and Type 5 bleeding, including puncture site bleeding, gastrointestinal bleeding, and intracranial hemorrhage.)\[1\]Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. PMID: 21670242.

    Time frame: 12 months

  3. Incidence of first BARC 1/2/3/5 bleeding within 12 months

    Incidence rate of bleeding events (Bleeding Academic Research Consortium (BARC)\[1\] defined Type1, Type2, Type 3 and Type 5 bleeding, including puncture site bleeding, gastrointestinal bleeding, and intracranial hemorrhage.)\[1\]Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. PMID: 21670242.

    Time frame: 12 months

  4. Incidence of target lesion failure (TLF) within 12 months

    defined as cardiac death, target vessel myocardial infarction, and target lesion revascularization

    Time frame: 12 months

  5. Incidence of different types of ischemic events within 12 months

    * All-cause death * Cardiac death * Ischemic stroke * Definite stent thrombosis * Target vessel revascularization

    Time frame: 12 months

  6. Discontinuation rate of continuous dual antiplatelet therapy;

    Time frame: 12 months

  7. Discontinuation rate of P2Y12 inhibitor

    discontinuation for ≥1 week

    Time frame: 12 months

  8. Discontinuation rate of aspirin

    discontinuation for ≥1 week

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • 1.Li PX.Long-term prognosis and influencing factors of high bleeding risk ACS patients after PCI [Master's Thesis]; 2023.2.Yin P,Qi JL,Liu YN,et al.China's disease burden study report 2005-2017.Chinese Circulation Journal 2019; 34(12):1145-1154.3.Liu MB,He XY,Yang XH,et al. Summary of "China Cardiovascular Health and Disease Report 2023"(Epidemiology of cardiovascular diseases and interventional diagnosis and treatment status). Chinese Journal of Interventional Cardiology 2024;32(10): 541-550.4.Tan MQ,Yin CE,Wang FJ.Interpretation of the 2018 updated universal definition of myocardial infarction.Journal of Practical Electrocardiology 2018; 27(06):381-385.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2028, 36 months later.

Of 243 non-industry observational studies under Acute Coronary Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 36 months is close to that.

Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 21, 2026
StartEst.
Dec 30, 2025
Primary completionEst.
Dec 30, 2028
CompletionEst.
Jun 30, 2029
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07354828
Lead sponsor
Shenyang Northern Hospital
Responsible party
Han Yaling (Director, clinical professor, Shenyang Northern Hospital) — Principal investigator
First posted
Jan 21, 2026
Start date
Dec 30, 2025 (estimated)
Primary completion
Dec 30, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Jan 21, 2026

Study contacts

Haiwei Liu, Professor
Contact
ifoliuhw@sina.com
024-288897260

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion